Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.

Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Akintujoye OM, Glazer PM, Sartorelli AC.

Int J Radiat Biol. 2012 Mar;88(3):277-85. doi: 10.3109/09553002.2012.638359. Epub 2011 Dec 20.

2.

Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.

Kim EY, Liu Y, Akintujoye OM, Shyam K, Grove TA, Sartorelli AC, Rockwell S.

Radiat Res. 2012 Sep;178(3):126-37. Epub 2012 Aug 3.

3.

Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.

Ishiguro K, Zhu YL, Shyam K, Penketh PG, Baumann RP, Sartorelli AC.

Biochem Pharmacol. 2010 Nov 1;80(9):1317-25. doi: 10.1016/j.bcp.2010.07.022. Epub 2010 Jul 21.

4.

KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.

Baumann RP, Ishiguro K, Penketh PG, Shyam K, Zhu R, Sartorelli AC.

Biochem Pharmacol. 2011 May 15;81(10):1201-10. doi: 10.1016/j.bcp.2011.02.019. Epub 2011 Mar 17.

5.

Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.

Zhu R, Baumann RP, Patridge E, Penketh PG, Shyam K, Ishiguro K, Sartorelli AC.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1853-9. doi: 10.1016/j.bmcl.2013.01.016. Epub 2013 Jan 11.

6.

A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions.

Penketh PG, Shyam K, Baumann RP, Ishiguro K, Patridge EV, Zhu R, Sartorelli AC.

Chem Biol Drug Des. 2012 Aug;80(2):279-90. doi: 10.1111/j.1747-0285.2012.01401.x. Epub 2012 May 23.

7.
8.

Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase.

Zhu R, Seow HA, Baumann RP, Ishiguro K, Penketh PG, Shyam K, Sartorelli AC.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6242-7. doi: 10.1016/j.bmcl.2012.08.008. Epub 2012 Aug 10.

9.

Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine.

Ishiguro K, Shyam K, Penketh PG, Sartorelli AC.

Mol Cancer Ther. 2005 Nov;4(11):1755-63.

10.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.

Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9282-7. Epub 2005 Jun 17.

11.

Clinical activity of laromustine (Onrigin™) in hematologic malignancies.

Alvarado Y, Swords R, Kelly KR, Giles FJ.

Expert Rev Hematol. 2009 Oct;2(5):481-8. doi: 10.1586/ehm.09.38.

PMID:
21083013
12.

Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.

Rizzieri D, LoRusso S, Tse W, Khan K, Advani A, Moore J, Karsten V, Cahill A, Gerson SL.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6. doi: 10.3816/CLML.2010.n.033.

PMID:
20511167
13.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity.

Baumann RP, Shyam K, Penketh PG, Remack JS, Brent TP, Sartorelli AC.

Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95. Epub 2003 Dec 17.

PMID:
14685775
14.

Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.

Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grénman R, Span PN, Bussink J.

BMC Cancer. 2012 Oct 10;12:463. doi: 10.1186/1471-2407-12-463.

15.

Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.

Pigneux A.

IDrugs. 2009 Jan;12(1):39-53. Review.

PMID:
19127504
16.

Combination therapy with radiation, mitomycin C, and 5-fluorouracil in EMT6 tumors.

Rockwell S.

Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):127-33.

PMID:
8270433
17.
18.
19.

Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

Donnelly ET, Kelley M, Rockwell S.

Cancer Chemother Pharmacol. 2004 Jan;53(1):43-50. Epub 2003 Oct 22.

PMID:
14574460
20.

Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.

Rice KP, Klinkerch EJ, Gerber SA, Schleicher TR, Kraus TJ, Buros CM.

Mol Cell Biochem. 2012 Nov;370(1-2):199-207. doi: 10.1007/s11010-012-1411-y. Epub 2012 Aug 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk